**Name of Journal: *World Journal of Stem Cells***

**ESPS Manuscript NO: 22478**

**Manuscript Type: Review**

# Homing and migration of mesenchymal stromal cells: How to improve the efficacy of cell therapy?

De Becker A *et al.* Mesenchymal stromal cell migration

**Ann De Becker, Ivan Van Riet**

**Ann De Becker, Ivan Van Riet,** Department Clinical Hematology - Stem Cell Laboratory, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel (VUB), 1090 Jette, Belgium

**Author contributions:** Both authors contributed equally to the conception of the paper, the literature review and analysis, and drafting, and to critically revising and editing the manuscript.

**Conflict-of-interest** **statement:** There are no potential conflicts of interest, as there was no financial support for this article.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to: Ivan Van Riet, MSc, PhD,** Department Clinical Hematology - Stem Cell Laboratory, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, 1090 Jette, Belgium. [ivan.vanriet@uzbrussel.be](mailto:ivan.vanriet@uzbrussel.be)

**Telephone:** +32-2-4776211

**Fax:** +32-2-4776210

**Received:** August 29, 2015

**Peer-review started:** September 6, 2015

**First decision:** November 11, 2015

**Revised:** December 24, 2015

**Accepted:** January 27, 2016

**Article in press:**

**Published online:**

# Abstract

Mesenchymal stromal cells (MSCs) are currently being investigated for use in a wide variety of clinical applications. For most of these applications, systemic delivery of the cells is preferred. However, this requires the homing and migration of MSCs to a target tissue. Although MSC homing has been described, this process does not appear to be highly efficacious because only a few cells reach the target tissue and remain there after systemic administration. This has been ascribed to low expression levels of homing molecules, the loss of expression of such molecules during expansion, and the heterogeneity of MSCs in cultures and MSC culture protocols. To overcome these limitations, different methods to improve the homing capacity of MSCs have been examined. Here, we review the current understanding of MSC homing, with a particular focus on homing to bone marrow. In addition, we summarize the strategies that have been developed to improve this process. A better understanding of MSC biology, MSC migration and homing mechanisms will allow us to prepare MSCs with optimal homing capacities. The efficacy of therapeutic applications is dependent on efficient delivery of the cells and can, therefore, only benefit from better insights into the homing mechanisms.

**Key words:** Mesenchymal stromal cells; Homing; Bone marrow; Homing receptors; Extravasation

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Mesenchymal stromal cells (MSCs) are currently under investigation for use in a variety of clinical applications. In most studies, MSCs are administered systemically. This requires efficient homing and migration of the MSCs to a target tissue. However, the homing mechanisms of MSCs are not completely understood. Moreover, the *in vivo* homing and migration of MSCs does not appear to be highly efficient. Therefore, different methods have been investigated to improve homing. Here, we will review the current knowledge of bone marrow homing of MSCs, as well as the different strategies that might improve the homing capacity of these stem cells.

# De Becker A, Van Riet I. Homing and migration of mesenchymal stromal cells: How to improve the efficacy of cell therapy? *World J Stem Cells* 2016; In press

# INTRODUCTION

Mesenchymal stromal cells (MSCs) are non-haematopoietic cells that were first derived from the bone marrow and described approximately 40 years ago by Friedenstein *et al*[1]. In 2006, the International Society for Cell Therapy defined the minimal criteria to define human MSCs. They must adhere to plastic in culture and differentiate into osteocytes, chondrocytes and adipocytes. Additionally they must express CD105, CD90 and CD73 and lack expression of CD45, CD34, CD14 or CD11b, CD79alpha or CD19, and HLA-DR surface molecules[2].

There is great interest in using these cells in a wide variety of clinical domains, such as Neurology, Orthopaedics, Cardiology and Haematology[3-6]. This interest arises from the following MSC characteristics: they have immunomodulatory capacities, they are multipotent and are thus possible effectors for tissue regeneration, and they tend to migrate to sites of tissue injury/inflammation[7-11]. Additionally MSCs might escape immune recognition, although conflicting observations about this particular phenotype have been published. MSCs do not express MHC class II antigens, but the expression of these molecules can be upregulated after exposure to inflammatory cytokines or during MSC differentiation[12]. The data from animal studies suggest that MSCs can elicit allogeneic immune responses and be rejected[13-16]. On the other hand, there is also a report of MSCs that overcame this allogeneic immune response due to their immunomodulatory capacities[17]. von Bahr *et al*[18] addressed this issue and published follow-up data of patients treated with MSCs, showing that there was no correlation between the MSC source (donor-derived or third party) and the patients’ response to the MSC treatment. The clinical applications of these cells have been extensively studied in Orthopaedics, where MSCs are used to repair large bone defects, and in Haematology for the treatment of graft-versus-host disease and support for the engraftment[4,6,19]. In recent years, MSCs have been studied as vehicles to deliver anti-cancer treatments because there is evidence that MSCs home to tumour sites. They can be induced to express anti-cancer proteins [*e.g.*, interleukin (IL) 2], to produce pro-drug activating enzymes, which ensures that the active drug will only be localized in the tumour, or to deliver oncolytic viruses[20-23]. For these applications, the homing and persistence of MSCs in the target tissue are desirable[24].

When MSCs are used in clinical applications, different modes of administration are possible: Systemic administration [intravenous (IV) or intra-arterial (IA) injection] or local administration [intracoronary (IC) injection or direct injection into the tissue of interest]. Of these different options, IV injection is the most widely used because it is minimally invasive, the infusions can be readily repeated and the cells will remain close to the oxygen- and nutrient-rich vasculature after extravasation into the target tissue[25]. However, after IV injection, the cells appear to be trapped in the lungs, and thus efficient homing to the target tissues might be compromised. IA administration requires an invasive procedure that has a higher risk of complications than IV. Although IA injections might improve tissue-specific homing compared to IV, there is a concern that microthrombi might occur as a result of trapping large MSCs in the microvasculature. One example is the concerns regarding IC injections of MSCs to treat myocardial infarction[26]. Similar concerns have been raised in studies that used MSCs to treat stroke[27,28]. A true local injection of MSCs might require a surgical intervention, such as that used in the repair of bone defects. In this setting, the MSCs are immediately delivered to the target tissue; however, the cells’ survival might be compromised due to a lack of oxygen or nutrients[25]. Currently, haematopoietic stem cell transplantation is performed *via* an IV infusion. Intra-bone marrow transplantation is a more complex procedure, but evidence from an animal model suggests that this might improve the outcome of the treatment[29]. Finally, some animal modes of systemic administration, such as intracardiac injection, cannot readily be performed in patients.

The systemic infusion of cells for therapeutic applications implies and requires efficient migration and homing to the target site. Although there is ample evidence of MSC homing, this process appears to be inefficient because only a small percentage of the systemically administered MSCs actually reach the target tissue[30]. The mechanisms by which the MSCs migrate and home are not yet clearly understood.

Currently, in Haematology, MSCs are mainly being tested for their ability to control graft-versus-host disease and to support haematopoiesis after haematopoietic stem cell transplantation. Chemo- and radio-therapy can damage the haematopoietic niche. MSCs are part of this niche and secrete a number of haematopoietic growth factors. To facilitate the engraftment of haematopoietic stem cells and stimulate blood formation, the MSCs should successfully home to and persist in the bone marrow[31]. In this review, we discuss current knowledge about MSC homing, specifically focusing on bone marrow homing (based on both *in vitro* and *in vivo* data), and we review the efforts that different groups have undertaken to improve the homing efficiency of these cells.

# MSC HOMING AND MIGRATION TO BONE MARROW AND OTHER TISSUES

The exact mechanisms used by MSCs to migrate and home to tissues have not been fully elucidated. It is generally assumed that these stem cells follow the same steps that were described for leukocyte homing. In the first step, the cells come into contact with the endothelium by tethering and rolling, resulting in a deceleration of the cells in the blood flow. In the second step, the cells are activated by G-protein-coupled receptors, followed by integrin-mediated, activation-dependent arrest in the third step. Finally, in the fourth step, the cells transmigrate through the endothelium and the underlying basement membrane[32].

The first studies addressing MSC homing examined the origin of the bone marrow MSCs after allogeneic bone marrow transplantation. Those groups all concluded that the haematopoietic cells were provided by the donor, but the stromal cells were provided by the recipient[33-35]. However, in these studies, the patients received marrow transplants containing only a limited number of MSCs - approximately 1/250000 nucleated cells at 35 years of age - in contrast to the purified MSC product that is used in the majority of clinical trials[36].

Since then, several studies in animal models and patients have shown that MSCs are capable of migrating and homing to a variety of tissues. Early studies of intra-uterine MSC transplantations in animal models showed that donor-derived non-haematopoietic cells were present in the bone marrow, thymus, spleen and liver[37,38]. Devine *et al*[30] and Chapel *et al*[7] performed MSC transplantations in non-human primates and observed MSCs in a variety of tissues, with highest numbers in the gastro-intestinal tract. The percentage of MSCs in the different tissues was estimated between 0.1% and 2.7%[7,30]. Erices *et al*[39] described the homing and survival of human cord blood-derived MSCs in the bone marrow of immunodeficient (nude) mice after systemic infusion[39]. Several studies in patients have also shown MSC homing[40-43].

A few groups have analysed the dynamics of MSC migration after systemic infusion using different techniques. Immediately after infusion, the MSCs are trapped in the lungs, and, subsequently, the cells are cleared from the lungs and distributed to other tissues[44,45]. The cells could be injected intravenously or intra-arterially for systemic infusion. The former is the least invasive method and the easiest to perform; however, as the MSCs were trapped in the lungs, different administration routes were examined. Intra-arterial injection, which is already more risky because of the arterial puncture, also appears to entail a risk of development of microvascular occlusions called passive entrapment[27,46]. In addition, there have been reports that MSCs have a procoagulant activity[26,47]. A few years ago, a group from the Karolinska Institute reported that MSCs, particularly those that had been subjected to extended passaging and co-culture with activated lymphocytes, exhibited increased prothrombotic capacities; this effect was dose-dependent[47]. Gleeson *et al*[26] reported that MSCs express functionally active tissue factor. When MSCs were injected in the coronary arteries of a porcine myocardial infarction model, it resulted in a decreased coronary flow reserve. This effect could be reversed by the co-administration of heparin, an antithrombin agent[26].

Kyriakou *et al*[48] have studied the factors influencing short-term bone marrow homing of MSCs. The stem cells were observed in the bone marrow, spleen, liver and lungs 24 h after intravenous injection. It was observed that homing increased in younger animals and after irradiation but decreased with increasing passage numbers of the cells[48]. Several other groups have also shown that MSC homing improves after irradiation[7,8,30,49-52].

# MOLECULES INVOLVED IN MSC (BONE MARROW) HOMING

The expression of molecules involved in MSC migration, homing and functionality has been widely studied.

Different molecules are involved/necessary for the different steps in the homing process. The selectins on the endothelium are primarily involved in the first step. For bone marrow homing in particular, the expression of haematopoietic cell E-/L-selectin ligand (HCELL), a specialized glycoform of CD44 on the migrating cell, is very important[53]. Although MSCs express CD44, they do not express HCELL[54].

The G-protein coupled receptors that are involved in the activation step are typically chemokine receptors. It has been extensively demonstrated that the CXCR4-stromal derived factor-1 (SDF-1) axis is critical for bone marrow homing[55]. Both molecules are very physiologically important, as knock-outs are lethal due to bone marrow failure and abnormal heart and brain development[56,57]. The expression of the chemokine receptor CXCR4 on MSCs is controversial. Some groups did not observe expression of the receptor, while other studies demonstrated that CXCR4 was expressed, albeit at low levels on the membrane, which affected migration in response to SDF-1[58-70].

Integrins are important players in the stable activation-dependent arrest in the third step of homing. It has been shown that the inhibition of integrin β1 can abrogate MSC homing[71]. Integrins form dimers that bind to adhesion molecules on the endothelial cells. Integrin α4 and β1 combine to form very late antigen 4 (VLA-4), which interacts with vascular cell adhesion molecule 1 (VCAM-1). It has been shown that the VCAM-1-VLA4 interaction is functionally involved in MSC homing[72,73].

In the final step of diapedesis or transmigration through the endothelial cell layer and the underlying basement membrane, lytic enzymes, such as the matrix metalloproteinases (MMP), are required to cleave the components of the basement membrane. In particular, the gelatinases MMP-2 and MMP-9 have important roles in this step because they preferentially degrade collagen and gelatin, two of the major components of the basement membrane[74,75]. We have shown that MSC migration is regulated by MMP-2 and tissue inhibitor of metalloproteinases 3 (TIMP-3)[76]. Membrane type 1 MMP (MT1-MMP) has also been reported to play a role in MSC migration[63]. MMPs are secreted as pro-enzymes. ProMMP-2 is activated by interactions with MT1-MMP and TIMP-2 and is inhibited by TIMP-1. This explains why the MMP-2, MT1-MMP or TIMP-2 knock-down decreased the invasive capacity of MSCs, and why TIMP-1 knock-down resulted in increased invasion in the study of Ries *et al*[77].

Table 1 gives an overview of all of the migration and homing molecules that are reported to be expressed on human MSCs. Figure 1 shows a schematic overview of the molecules involved in human MSC bone marrow homing.

In addition to the expression of classic homing molecules, different groups have also described the expression of growth factor receptors on MSCs. Several studies have shown that growth factors can also induce MSC migration. For example, platelet-derived growth factor (PDGF) AB and BB can induce MSC migration *in vitro*[68,80,91]. Another growth factor involved in MSC migration is hepatocyte growth factor (HGF), which binds to c-met[63,68,80]. Both PDGF-BB and HGF have been loaded on gels or scaffolds as a means to improve the *in vitro* migration of MSCs[92,93].

# HOW CAN WE IMPROVE THE HOMING EFFICIENCY OF MSCs?

Several groups have demonstrated MSC homing and migration, but only a small proportion of systemically administered MSCs actually reaches and remains in the target tissue[30]. Several factors are assumed to be involved in this process. First, the expression of homing molecules on MSCs is limited. For example, the membrane expression of CXCR4, a critical receptor for homing to bone marrow, is very low, and some groups even claim there is no CXCR4 expression at all[58-70]. Another concern is that the MSCs appear to lose the expression of homing molecules during *in vitro* expansion[70,94]. Additionally, there is also heterogeneous expression of homing molecules in MSC cultures and in MSCs derived from different tissues (adipose tissue *vs* bone marrow), which show a different expression profile of homing molecules[95].

Because improving the homing efficiency to and retention of MSCs in a target tissue after systemic administration would improve their therapeutic effects, many groups are investigating methods to achieve this goal. Different strategies have been developed: the mode of administration could be modified, the MSC culture conditions can be adapted to optimize the expression of homing molecules, the cell surface receptors could be engineered to improve homing or the target tissue could be modified to better attract the MSCs. Again, we will mainly focus on the strategies that might improve the bone marrow homing of MSCs. Not all of the studies that we reviewed focused on improving bone marrow homing. The homing molecules involved in homing to bone marrow can also be of importance in homing to other organs or sites of injury, such as the CXCR4-SDF-1 interaction for homing to the injured myocardium[96]. However, we believe that methods that can upregulate or induce the expression of the homing molecules that are involved in bone marrow homing of MSCs are valuable. They show a potential means for improving bone marrow homing, even though the data supporting/proving this are not yet available. Figure 2 provides an overview of the methods that could be used to improve the bone marrow homing of MSCs.

# *Modification of the mode of administration*

*In vivo* studies have repeatedly shown that MSCs are trapped in the lung after intravenous injection. When mice were treated with a vasodilator prior to MSC infusion, there was a clear decrease in the number of trapped MSCs in the lungs and a significant increase in MSC homing to the marrow of the long bones[44]. Yukawa *et al*[97] transplanted MSCs in combination with heparin treatment and found that this strategy also significantly decreased MSC trapping in the lungs.

# *Pretreatment or priming of MSCs in culture or modifying the MSC culture conditions*

Because MSCs appear to downregulate homing molecule expression during expansion, many groups are investigating different ways to induce or upregulate the expression of important homing molecules.

Much effort has been focused on increasing CXCR4 expression on the membrane. One way to achieve this is by adding cytokines or cytokine cocktails to the culture medium during expansion. Shi *et al*[66] showed that exposure to a combination of flt3 ligand, stem cell factor (SCF), IL 3, IL 6 and hepatocyte growth factor (HGF) increased both the intracellular and membrane expression of CXCR4 on cultured MSCs. More of the pretreated cells migrated towards an SDF-1 gradient, and there was no effect of the pretreatment on the function of the MSCs in supporting haematopoiesis. *In vivo* homing experiments where MSCs were intravenously injected into sublethally irradiated mice revealed a significant increase in bone marrow homing after the cytokine treatment[66]. Other molecules that have been shown to increase CXCR4 expression are insulin-like growth factor 1 (IGF-1), tumour necrosis factor α (TNFα), IL 1β, interferon γ (IFNγ)[68,98-100]. CXCR4 expression could also be upregulated by treating cultured MSCs with glycogen synthase kinase 3β (GSK-3β) inhibitors, resulting in an improved *in vitro* migration capacity, without affecting cell viability[101]. Exposure to complement 1q (C1q) has been shown to increase MSC migration towards SDF-1, although there was no significant increase in CXCR4 expression. Therefore, it was postulated that C1q exposure increases the MSCs’ ability to sense SDF-1 gradients[65].

Treatments with GSK-3β inhibitors and C1q also increase MMP expression in MSCs, which are important for the degradation of the basement membrane during extravasation[60,101]. A combination of the haematopoietic growth factors erythropoietin (EPO) and granulocyte colony stimulating factor (G-CSF) has also been reported to increase MMP-2 expression in MSCs and improve their motility[102].

There is also evidence that the epigenetic modulation induced by a short-term exposure to valproic acid results in increased expression of CXCR4 and MMP-2 in cultured MSCs and an increase in their migration towards SDF-1. There was no impact of this priming on the differentiation capacity of the cells[103].

Another approach that is under investigation is culturing MSCs under hypoxic conditions. Several groups have shown that these conditions result in increased CXCR4 expression and an improvement in MSC migration both *in vitro* and *in vivo*. This effect of hypoxia not only appears after short-term exposure but also in response to continuous culture in hypoxic conditions[104-108]. The increase in CXCR4 expression is reported to be regulated by an increase in hypoxia inducible factor (HIF) 1α[108]. Hypoxia also leads to differential expression of MMPs. For example, a decrease in MMP-2 secretion and an increase in MT1-MMP secretion and activity has been described in MSCs cultured under hypoxic conditions[104]. However, one could be concerned that culturing MSCs under hypoxia might change their behaviour. Valorani *et al*[109] reported that adipose tissue-derived MSCs cultured under hypoxic conditions exhibited an increased adipogenic or osteogenic differentiation capacity[109]. Crowder *et al*[110] reported that concurrent exposure to extreme hypoxia (0.5%) and a carcinogenic metal (nickel) induces carcinogenic changes in late passage MSCs. They did not observe these changes in early passage control cells[110].

A simpler modification of culture conditions is to maintain lower confluence. Our group found that MSCs that were cultured to complete confluence had a lower migration capacity than MSCs maintained at a low confluence. The cells cultured at higher confluence secrete more TIMP-3, an inhibitor of MMPs, which decreases migration compared to the MSCs cultured at low confluence[76].

Finally, MSCs are a heterogeneous cell population, and a particular subset of MSCs might have better homing abilities. MSCs were separated based on their expression of Stro1 and cultured further; these cells exhibited different migration capacities in NOD/SCID transplantation experiments. The amount of Stro1- MSCs was higher than the amount of Stro1+ MSCs in the target tissues of the mice, such as the bone marrow and spleen, after systemic administration *via* the retro-orbital plexus[111].

# *Genetic modifications*

As already mentioned, MSCs only express low levels of CXCR4, if any at all[58,59]. Because the CXCR4-SDF1 axis is important for bone marrow homing[20,112], many groups have designed transfection or transduction experiments in which CXCR4 expression plasmids are either nonvirally or virally introduced into the cells. Viral transduction is the most efficient method for obtaining high and stable expression levels in the target cells. CXCR4 overexpression resulted in improved MSC homing to the bone marrow after intracardiac injection into a NOD/SCID transplant model[112]. In a similar model, the overexpression of integrin α4, a subunit of VLA4 that interacts with VCAM-1, also resulted in increased bone marrow homing[113]. However, there are some draw-backs to this technique. Most importantly, there is the concern that the use of viral vectors to introduce the plasmid DNA poses a risk of insertional oncogenesis. Techniques for site-directed integration have been developed to circumvent this problem[114]. Moreover, there is also a risk of adverse immune reactions and the production costs are high[115].

Different modes of non-viral transfection of plasmid DNA have been developed. One group overexpressed CXCR4 in MSCs using mRNA nucleofection. They obtained 90% expression of the surface receptor, but cell viability was only 62% and no increase in MSC homing could be observed[96]. Another group investigated the feasibility of inserting a short interfering RNA in MSCs using ultrasound and microbubbles to promote survival. A significant knock-down of the target (PTEN) could be obtained, but the cells were damaged after the manipulation[116].

Different modes of chemical, non-viral transfection have been studied, including the use of lipid agents. Although these techniques are easier to scale up and less expensive than viral transduction, they come with a price. The transfection efficiencies are significantly lower because approximately 35% of the MSCs express the transfected protein compared to over 90% of the cells after viral transduction[20].

# *Cell surface engineering*

A method to improve homing efficiency of MSCs that has garnered interest in recent years is cell surface engineering, *i.e.*, a transient modification of the cell surface. Because transmigration through the activated endothelium takes 1-2 h, these transient alterations can be instrumental in improving MSC homing[117]. It has been shown that these modifications do not impact cell viability, proliferation, adhesion or differentiation[118-121]. For cell surface engineering, most groups focus on improving the first step of the homing process, tethering and rolling, by modulating the expression of adhesion molecules[54,118,120,121]. Since the first publications, many groups have developed different techniques for the cell surface modifications of MSCs.

A seminal paper in this field was published in 2008, when Sackstein *et al*[54] reported that they had converted the native CD44, which is readily expressed on MSCs, into the haematopoietic cell E-selectin/L-selectin ligand (HCELL) glycoform *ex vivo*[54]. E-selectin plays a key role in haematopoietic stem cell (HSC) homing to the bone marrow; however, MSCs do not express P-selectin glycoprotein ligand-1 (PSGL-1) or HCELL, the two E-selectin ligands that are required for HSC bone marrow homing, thus impairing their homing capacity to the bone marrow[54,122]. MSCs natively express CD44. In this study, Sackstein *et al*[54] were able to alter sialofucosylation *ex vivo* and transform CD44 into the HCELL glycoform. This treatment had no effect on the viability or phenotype of the cells. *In vivo* homing experiments that injected MSCs into the tail veins of NOD/SCID mice showed that the HCELL+ MSCs homed to the bone marrow, even in the absence of CXCR4, in contrast to the unmanipulated MSCs[54].

Sialyl Lewis X (SLEX) is the active site of PSGL-1. Therefore, introducing this molecule into the MSC cell membrane should also lead to improved MSC homing. Sarkar *et al*[118] used biotinylated microvesicles to modify the MSCs. When the vesicles were brought into contact with the MSCs, they integrated into the cell membrane, thus generating biotinylated MSCs. Using a streptavidin linker, biotinylated SLEX could be immobilized on the cell surface. The accessibility of the lipids integrated in the cell membrane was assessed and the researchers found they could still be detected after 4 h, but the intensity had already decreased to 50% compared with that at 0 h. After 8 h, all signals were lost, confirming that the modification is indeed transient. *In vitro* tests showed that the SLEX-expressing MSCs exhibited improved adhesion under shear stress compared to the sham-treated MSCs[118].

Cheng *et al*[120] described a rapid (30 min) procedure to conjugate peptide K, an E-selectin binding peptide, to the MSC membrane. The MSC viability and proliferation rates were normal after engineering and their differentiation capacity was also maintained. In an *in vitro* model of inflamed endothelium, they subsequently demonstrated that the engineered MSCs adhered better than the control MSCs under shear stress[120].

Lo *et al*[121] described yet another engineering method to improve MSC binding to selectins and facilitate tethering and rolling. The first 19 amino acids of PSGL-1 (Fc19) were combined with an IgG tail and with an SLEX glycan to engineer a pan-selectin-binding ligand. Tests in flow chambers showed that these MSCs were indeed capable of adhesion under shear stresses[121].

However, adhesion molecules are not the sole targets of the cell surface engineers. There is also interest in conjugating antibodies to the cell surface. Protein painting is a technique that binds antibodies to the cell surface. First, the palmitated proteins acting as docking stations for the antibodies are integrated into the cell membrane, and, subsequently, antibodies can be bound to the cell without losing affinity and with no impact on the viability and differentiation potential of the engineered cells[123]. One example using this technique is the binding of intercellular adhesion molecule (ICAM)-1 antibodies to MSCs, which increased the binding of these cells to endothelial cells[124]. This same protein painting technique has been applied to express VCAM-1 antibodies on MSCs, resulting in improved homing. In this study, the target tissues were the mesenteric lymph nodes and the colon. However, this technique might also be applied to improve homing to other organs, such as the bone marrow, because VCAM-1 is implicated in the bone marrow homing of MSCs[125].

Recently, a method was also described in which recombinant CXCR4 is bound to the cell surface of MSCs using lipid-PEG. In a one-step mixture procedure, recombinant CXCR4 could be transiently expressed on MSCs, leading to migration towards SDF-1 in a concentration-dependent manner[119].

# *Modification of the target tissue*

Finally, MSC migration and homing can be influenced by modifying the target tissue. In early homing studies, it was already shown that altering the target tissue by irradiation increases MSC homing[7,8]. After chemo- and radio-therapy, there are increased levels of SDF-1 in the bone marrow, thus increasing its attraction for HSCs and MSCs[126]. There are also reports of manipulating MSC migration with ultrasound or magnetic or electric fields[127-129]. However, these techniques do not appear to be very practical and they need adequate expression of homing molecules. For example, application of electrical fields could induce heat and electrochemical products near the electrodes. On the other hand, ultrasound-guided delivery might be more challenging in deep organs. Finally, homing directed by a magnetic field might require the implantation of a magnet in or near the tissue of interest[127-129].

***Caveats in modifying homing molecules***

In animal models and clinical studies, only limited engraftment or no engraftment at all is often observed, raising the question of whether tissue-specific homing is required for the therapeutic effect of MSCs[30,42]. A study on the use of systemically administered MSCs for the treatment of stroke in an animal model also showed very limited migration of MSCs to the tissue of interest, the brain. However, the researchers found that MSC homing to the spleen was important and correlated with a reduced infarct size and peri-infarct inflammation. They propose that MSCs exert a beneficial effect by abrogating secondary, inflammation-related cell death[130]. These data show that tissue-specific MSC homing is important, even though the target tissue is not the brain, as one would expect in a stroke model. Fernández-García *et al*[131] performed cotransplantation studies with MSCs and HSCs and found that cotransplantation improves short- and long-term haematopoietic reconstitution. This was the result of MSC and HSC interactions, and they propose that MSCs act as carriers that facilitate HSC homing to the bone marrow[131].

Manipulating stem cells, such as MSCs, to improve their homing capacities might not only change their migratory capacities but also have other consequences. For example, Liu *et al*[132] claim that the CXCR4-SDF-1 axis plays an important role in MSC survival because MSCs pretreated with SDF-1 exhibited significantly improved survival and proliferation. These effects could be partially inhibited by AMD3100, an inhibitor of CXCR4[132]. The pretreatment of MSCs with cytokines also revealed some conflicting observations. In a recently published paper, Kavanagh *et al*[133] report that licensing murine MSCs with inflammatory cytokines does not improve homing to the injured gut in an ischaemia/reperfusion model in their hands. More importantly, they found that while the untreated MSCs improved tissue perfusion, this effect was abrogated with the pretreated MSCs[133]. However, another group reported positive effects of pretreatment on the biological functions of the MSCs. Szabó*et al*[134] found that licensing murine MSCs with pro-inflammatory cytokines resulted in a significant reduction in the variability in immunosuppressive capacities of these MSCs. This reduction in variability was due to an increased immunosuppression of clones that were poor inhibitors of T-cell proliferation prior to licensing[134].

The pretreatment of MSCs with different factors or conditions, *e.g.*, hypoxia and inflammatory cytokines, could also modify their response to these treatments. Naaldijk *et al*[135] found that the oxygen concentration (normoxia *vs* hypoxia) alters the response of rat and human AT MSCs. They also found that the migration of MSCs isolated from older donors (rat and human) was not significantly impaired compared with the MSCs from young donors[135]. In contrast to this last finding, Choudery described that MSCs from aged mice exhibit diminished effectiveness and increased expression of apoptotic and senescent genes[136].

In this review, we have described different techniques for improving MSC homing and the expression of homing molecules on MSCs. Importantly, however, the expression of homing molecules and the resulting migration, homing and biological functions of MSCs might easily be altered unintentionally. Currently, many different protocols are used to expand MSCs for *in vitro*, animal and clinical studies. These variables can have a major impact on the expression of the homing molecules and the biological functions of MSCs; we will briefly discuss this below.

MSCs were first isolated from bone marrow (BM). Since then, MSCs have been isolated from a wide variety of tissues, including adipose tissue (AT), umbilical cord blood (CB), Wharton’s jelly (WJ), *etc*.[59,79,80,82]. Several groups have reported differences in the expression of homing molecules in human MSCs isolated from different sources; these are listed in Table 1. Additionally, the MSCs derived from different sources also exhibit differences in their biological functions. For example, AT MSCs might have better immunosuppressive capacities than BM MSCs[95]. On the other hand, BM MSCs appear to be the only MSCs that are capable of forming a haematopoietic niche that can support human haematopoietic tissue in an *in vivo* model[87].

When using MSCs for organ-specific treatments, one might choose to induce differentiation *in vitro* before transplantation. However, *in vitro* differentiation might not always result in a clinical benefit during MSC therapy. In a study using human CB MSCs in a mouse model for liver disease, the researchers found that hepatic differentiated MSCs performed worse than the undifferentiated MSCs. The differentiated MSCs showed decreased expression of the homing molecules and decreased *in vivo* migration after IV infusion. Additionally, their immunosuppressive capacity was decreased and the expression of HLA DR was increased, thus increasing their immunogenicity[137]. Ullah *et al*[138] also found that chondrogenic differentiated human MSCs exhibited a significantly reduced *in vitro* migration capacity than undifferentiated MSCs. However, CCR9 expression and *in vitro* migration to its ligand, CCL25, were retained in the differentiated MSCs[138].

Many parameters in MSC cultures vary between different research groups, including seeding density, number of passages, basal medium, and growth supplements [foetal bovine serum (FBS) *vs* platelet lysate (PL)]. All of these factors might have an important impact on MSC function and migration. For example, Cholewa *et al*[139] found that PL increased MSC proliferation and increased the number of population doublings before senescence compared to FBS. However, they also showed that seeding MSCs at lower densities selected a highly migratory MSC population[139]. There are also reports of MSCs losing their migratory capacity and/or expression of homing molecules after *ex vivo* expansion[48,94]. After culture, MSCs are harvested with trypsin to detach them for passaging. Chamberlain *et al*[140] reported that the cell surface expression of chemokine receptors was decreased when the cells were detached with trypsin.

***Future research directions***

As described above, there is currently substantial variability in the isolation and expansion protocols for MSCs. Research on MSC homing and migration would clearly benefit from standardized MSC expansion protocols. What appears to be a rather minor aspect of the expansion protocol might have a significant impact on MSC function and/or migration. Thus, standardizing MSC expansion protocols would minimize unintentional modifications of the homing molecules. Of course, different culture conditions should be compared to create an optimal expansion protocol. Once this protocol is defined, it will also be easier to evaluate therapeutic efficacy of MSCs in clinical settings. It may be that different clinical applications require different expansion protocols to obtain the desired therapeutic effect.

We summarized the strategies for improving MSC homing. Many of these methods have not yet been validated *in vivo*. Before they can be translated to the clinic, the techniques with the most promising results should be first validated using *in vivo* homing models. In these experiments, the migration of engineered MSCs should be compared with the migration of untreated cells, and the therapeutic efficacy of the treated MSCs can also be assessed in animal disease models.

Although MSCs are widely studied and used in many clinical trials in a variety of clinical domains, little is known about the exact mechanisms by which MSCs exert certain therapeutic effects and their homing to certain tissues. Further studies would benefit from a better understanding of MSC biology. Understanding whether and where MSC migration or homing is necessary can help to define the optimal expansion protocols.

Finally, when transitioning to clinical trials, all conditions should be strictly defined, and, ideally, randomized controlled trials would be designed.

# CONCLUSION

MSCs are interesting effector cells that can be used in a variety of therapeutic applications. Systemic administration is often the preferred route of delivery. However, this approach requires that adequate numbers of MSCs migrate and home to the target tissue(s). MSCs do not express many homing receptors, which impairs their migration capacity and hampers their therapeutic efficacy. Studies are ongoing and are needed to further elucidate the MSC homing mechanisms. A better understanding of MSC homing, as well as the factors influencing this process, will allow researchers to optimize the migration capacities of these stem cells and their therapeutic effects in a target tissue.

# REFERENCES

1 **Friedenstein AJ**, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. *Transplantation* 1974; **17**: 331-340 [PMID: 4150881]

2 **Dominici M**, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 2006; **8**: 315-317 [PMID: 16923606]

3 **Wang C**, Fei Y, Xu C, Zhao Y, Pan Y. Bone marrow mesenchymal stem cells ameliorate neurological deficits and blood-brain barrier dysfunction after intracerebral hemorrhage in spontaneously hypertensive rats. *Int J Clin Exp Pathol* 2015; **8**: 4715-4724 [PMID: 26191161]

4 **Bashir J**, Sherman A, Lee H, Kaplan L, Hare JM. Mesenchymal stem cell therapies in the treatment of musculoskeletal diseases. *PM R* 2014; **6**: 61-69 [PMID: 24439148 DOI: 10.1016/j.pmrj.2013.05.007]

5 **Chou SH**, Lin SZ, Kuo WW, Pai P, Lin JY, Lai CH, Kuo CH, Lin KH, Tsai FJ, Huang CY. Mesenchymal stem cell insights: prospects in cardiovascular therapy. *Cell Transplant* 2014; **23**: 513-529 [PMID: 24816448 DOI: 10.3727/096368914X678436]

6 **De Becker A**, Van Riet I. Mesenchymal Stromal Cell Therapy in Hematology: From Laboratory to Clinic and Back Again. *Stem Cells Dev* 2015; **24**: 1713-1729 [PMID: 25923433 DOI: 10.1089/scd.2014.0564]

7 **Chapel A**, Bertho JM, Bensidhoum M, Fouillard L, Young RG, Frick J, Demarquay C, Cuvelier F, Mathieu E, Trompier F, Dudoignon N, Germain C, Mazurier C, Aigueperse J, Borneman J, Gorin NC, Gourmelon P, Thierry D. Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome. *J Gene Med* 2003; **5**: 1028-1038 [PMID: 14661178 DOI: 10.1002/jgm.452]

8 **Mouiseddine M**, François S, Semont A, Sache A, Allenet B, Mathieu N, Frick J, Thierry D, Chapel A. Human mesenchymal stem cells home specifically to radiation-injured tissues in a non-obese diabetes/severe combined immunodeficiency mouse model. *Br J Radiol* 2007; **80** Spec No 1: S49-S55 [PMID: 17704326 DOI: 10.1259/bjr/25927054]

9 **Nasef A**, Mathieu N, Chapel A, Frick J, François S, Mazurier C, Boutarfa A, Bouchet S, Gorin NC, Thierry D, Fouillard L. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. *Transplantation* 2007; **84**: 231-237 [PMID: 17667815 DOI: 10.1097/01.tp.0000267918.07906.08]

10 **Nasef A**, Chapel A, Mazurier C, Bouchet S, Lopez M, Mathieu N, Sensebé L, Zhang Y, Gorin NC, Thierry D, Fouillard L. Identification of IL-10 and TGF-beta transcripts involved in the inhibition of T-lymphocyte proliferation during cell contact with human mesenchymal stem cells. *Gene Expr* 2007; **13**: 217-226 [PMID: 17605296 DOI: 10.3727/000000006780666957]

11 **Nasef A**, Zhang YZ, Mazurier C, Bouchet S, Bensidhoum M, Francois S, Gorin NC, Lopez M, Thierry D, Fouillard L, Chapel A. Selected Stro-1-enriched bone marrow stromal cells display a major suppressive effect on lymphocyte proliferation. *Int J Lab Hematol* 2009; **31**: 9-19 [PMID: 19143868 DOI: 10.1111/j.1751-553X.2007.00997.x]

12 **Le Blanc K**, Ringdén O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant* 2005; **11**: 321-334 [PMID: 15846285]

13 **Isakova IA**, Lanclos C, Bruhn J, Kuroda MJ, Baker KC, Krishnappa V, Phinney DG. Allo-reactivity of mesenchymal stem cells in rhesus macaques is dose and haplotype dependent and limits durable cell engraftment in vivo. *PLoS One* 2014; **9**: e87238 [PMID: 24489878 DOI: 10.1371/journal.pone.0087238]

14 **Eliopoulos N**, Stagg J, Lejeune L, Pommey S, Galipeau J. Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. *Blood* 2005; **106**: 4057-4065 [PMID: 16118325 DOI: 10.1182/blood-2005-03-1004]

15 **Nauta AJ**, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. *Blood* 2006; **108**: 2114-2120 [PMID: 16690970 DOI: 10.1182/blood-2005-11-011650]

16 **Poncelet AJ**, Vercruysse J, Saliez A, Gianello P. Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo. *Transplantation* 2007; **83**: 783-790 [PMID: 17414713]

17 **Oh W**, Kim DS, Yang YS, Lee JK. Immunological properties of umbilical cord blood-derived mesenchymal stromal cells. *Cell Immunol* 2008; **251**: 116-123 [PMID: 18495100 DOI: 10.1016/j.cellimm.2008.04.003]

18 **von Bahr L**, Sundberg B, Lönnies L, Sander B, Karbach H, Hägglund H, Ljungman P, Gustafsson B, Karlsson H, Le Blanc K, Ringdén O. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. *Biol Blood Marrow Transplant* 2012; **18**: 557-564 [PMID: 21820393 DOI: 10.1016/j.bbmt.2011.07.023]

19 **Fouillard L**, Chapel A, Bories D, Bouchet S, Costa JM, Rouard H, Hervé P, Gourmelon P, Thierry D, Lopez M, Gorin NC. Infusion of allogeneic-related HLA mismatched mesenchymal stem cells for the treatment of incomplete engraftment following autologous haematopoietic stem cell transplantation. *Leukemia* 2007; **21**: 568-570 [PMID: 17252011 DOI: 10.1038/sj.leu.2404550]

20 **Park JS**, Suryaprakash S, Lao YH, Leong KW. Engineering mesenchymal stem cells for regenerative medicine and drug delivery. *Methods* 2015; **84**: 3-16 [PMID: 25770356 DOI: 10.1016/j.ymeth.2015.03.002]

21 **Qiao B**, Shui W, Cai L, Guo S, Jiang D. Human mesenchymal stem cells as delivery of osteoprotegerin gene: homing and therapeutic effect for osteosarcoma. *Drug Des Devel Ther* 2015; **9**: 969-976 [PMID: 25733814 DOI: 10.2147/DDDT.S77116]

22 **Hammer K**, Kazcorowski A, Liu L, Behr M, Schemmer P, Herr I, Nettelbeck DM. Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells. *Int J Cancer* 2015; **137**: 978-990 [PMID: 25604186 DOI: 10.1002/ijc.29442]

23 **Ďuriniková E**, Kučerová L, Matúšková M. Mesenchymal stromal cells retrovirally transduced with prodrug-converting genes are suitable vehicles for cancer gene therapy. *Acta Virol* 2014; **58**: 1-13 [PMID: 24717023 DOI: 10.4149/av\_2014\_01\_3]

24 **François S**, Usunier B, Douay L, Benderitter M, Chapel A. Long-Term Quantitative Biodistribution and Side Effects of Human Mesenchymal Stem Cells (hMSCs) Engraftment in NOD/SCID Mice following Irradiation. *Stem Cells Int* 2014; **2014**: 939275 [PMID: 24672555 DOI: 10.1155/2014/939275]

25 **Sarkar D**, Spencer JA, Phillips JA, Zhao W, Schafer S, Spelke DP, Mortensen LJ, Ruiz JP, Vemula PK, Sridharan R, Kumar S, Karnik R, Lin CP, Karp JM. Engineered cell homing. *Blood* 2011; **118**: e184-e191 [PMID: 22034631 DOI: 10.1182/blood-2010-10-311464]

26 **Gleeson BM**, Martin K, Ali MT, Kumar AH, Pillai MG, Kumar SP, O'Sullivan JF, Whelan D, Stocca A, Khider W, Barry FP, O'Brien T, Caplice NM. Bone Marrow-Derived Mesenchymal Stem Cells Have Innate Procoagulant Activity and Cause Microvascular Obstruction Following Intracoronary Delivery: Amelioration by Antithrombin Therapy. *Stem Cells* 2015; **33**: 2726-2737 [PMID: 25969127 DOI: 10.1002/stem.2050]

27 **Walczak P**, Zhang J, Gilad AA, Kedziorek DA, Ruiz-Cabello J, Young RG, Pittenger MF, van Zijl PC, Huang J, Bulte JW. Dual-modality monitoring of targeted intraarterial delivery of mesenchymal stem cells after transient ischemia. *Stroke* 2008; **39**: 1569-1574 [PMID: 18323495 DOI: 10.1161/STROKEAHA.107.502047]

28 **Misra V**, Ritchie MM, Stone LL, Low WC, Janardhan V. Stem cell therapy in ischemic stroke: role of IV and intra-arterial therapy. *Neurology* 2012; **79**: S207-S212 [PMID: 23008400]

29 **Ikehara S**. A novel BMT technique for treatment of various currently intractable diseases. *Best Pract Res Clin Haematol* 2011; **24**: 477-483 [PMID: 21925101 DOI: 10.1016/j.beha.2011.04.003]

30 **Devine SM**, Cobbs C, Jennings M, Bartholomew A, Hoffman R. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. *Blood* 2003; **101**: 2999-3001 [PMID: 12480709 DOI: 10.1182/blood-2002-06-1830]

31 **Fouillard L**, Francois S, Bouchet S, Bensidhoum M, Elm'selmi A, Chapel A. Innovative cell therapy in the treatment of serious adverse events related to both chemo-radiotherapy protocol and acute myeloid leukemia syndrome: the infusion of mesenchymal stem cells post-treatment reduces hematopoietic toxicity and promotes hematopoietic reconstitution. *Curr Pharm Biotechnol* 2013; **14**: 842-848 [PMID: 24372262 DOI: 10.2174/1389201014666131227120222]

32 **Butcher EC**, Picker LJ. Lymphocyte homing and homeostasis. *Science* 1996; **272**: 60-66 [PMID: 8600538 DOI: 10.1126/science.272.5258.60]

33 **Agematsu K**, Nakahori Y. Recipient origin of bone marrow-derived fibroblastic stromal cells during all periods following bone marrow transplantation in humans. *Br J Haematol* 1991; **79**: 359-365 [PMID: 1751363 DOI: 10.1111/j.1365-2141.1991.tb08041.x]

34 **Santucci MA**, Trabetti E, Martinelli G, Buzzi M, Zaccaria A, Pileri S, Farabegoli P, Sabattini E, Tura S, Pignatti PF. Host origin of bone marrow fibroblasts following allogeneic bone marrow transplantation for chronic myeloid leukemia. *Bone Marrow Transplant* 1992; **10**: 255-259 [PMID: 1422479]

35 **Koç ON**, Peters C, Aubourg P, Raghavan S, Dyhouse S, DeGasperi R, Kolodny EH, Yoseph YB, Gerson SL, Lazarus HM, Caplan AI, Watkins PA, Krivit W. Bone marrow-derived mesenchymal stem cells remain host-derived despite successful hematopoietic engraftment after allogeneic transplantation in patients with lysosomal and peroxisomal storage diseases. *Exp Hematol* 1999; **27**: 1675-1681 [PMID: 10560915 DOI: 10.1016/S0301-472X(99)00101-0]

36 **Caplan AI**. The mesengenic process. *Clin Plast Surg* 1994; **21**: 429-435 [PMID: 7924141]

37 **Almeida-Porada G**, Porada CD, Tran N, Zanjani ED. Cotransplantation of human stromal cell progenitors into preimmune fetal sheep results in early appearance of human donor cells in circulation and boosts cell levels in bone marrow at later time points after transplantation. *Blood* 2000; **95**: 3620-3627 [PMID: 10828053]

38 **Liechty KW**, MacKenzie TC, Shaaban AF, Radu A, Moseley AM, Deans R, Marshak DR, Flake AW. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. *Nat Med* 2000; **6**: 1282-1286 [PMID: 11062543 DOI: 10.1038/81395]

39 **Erices AA**, Allers CI, Conget PA, Rojas CV, Minguell JJ. Human cord blood-derived mesenchymal stem cells home and survive in the marrow of immunodeficient mice after systemic infusion. *Cell Transplant* 2003; **12**: 555-561 [PMID: 14579923 DOI: 10.3727/000000003108747154]

40 **Meleshko A**, Prakharenia I, Kletski S, Isaikina Y. Chimerism of allogeneic mesenchymal cells in bone marrow, liver, and spleen after mesenchymal stem cells infusion. *Pediatr Transplant* 2013; **17**: E189-E194 [PMID: 24164832 DOI: 10.1111/petr.12168]

41 **Koç ON**, Day J, Nieder M, Gerson SL, Lazarus HM, Krivit W. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). *Bone Marrow Transplant* 2002; **30**: 215-222 [PMID: 12203137 DOI: 10.1038/sj.bmt.1703650]

42 **Horwitz EM**, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, Muul L, Hofmann T. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. *Proc Natl Acad Sci USA* 2002; **99**: 8932-8937 [PMID: 12084934 DOI: 10.1073/pnas.132252399]

43 **Ringdén O**, Uzunel M, Sundberg B, Lönnies L, Nava S, Gustafsson J, Henningsohn L, Le Blanc K. Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon. *Leukemia* 2007; **21**: 2271-2276 [PMID: 17611560 DOI: 10.1038/sj.leu.2404833]

44 **Gao J**, Dennis JE, Muzic RF, Lundberg M, Caplan AI. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. *Cells Tissues Organs* 2001; **169**: 12-20 [PMID: 11340257 DOI: 10.1159/000047856]

45 **Bentzon JF**, Stenderup K, Hansen FD, Schroder HD, Abdallah BM, Jensen TG, Kassem M. Tissue distribution and engraftment of human mesenchymal stem cells immortalized by human telomerase reverse transcriptase gene. *Biochem Biophys Res Commun* 2005; **330**: 633-640 [PMID: 15809044 DOI: 10.1016/j.bbrc.2005.03.072]

46 **Karp JM**, Leng Teo GS. Mesenchymal stem cell homing: the devil is in the details. *Cell Stem Cell* 2009; **4**: 206-216 [PMID: 19265660 DOI: 10.1016/j.stem.2009.02.001]

47 **Moll G**, Rasmusson-Duprez I, von Bahr L, Connolly-Andersen AM, Elgue G, Funke L, Hamad OA, Lönnies H, Magnusson PU, Sanchez J, Teramura Y, Nilsson-Ekdahl K, Ringdén O, Korsgren O, Nilsson B, Le Blanc K. Are therapeutic human mesenchymal stromal cells compatible with human blood? *Stem Cells* 2012; **30**: 1565-1574 [PMID: 22522999 DOI: 10.1002/stem.1111]

48 **Kyriakou C**, Rabin N, Pizzey A, Nathwani A, Yong K. Factors that influence short-term homing of human bone marrow-derived mesenchymal stem cells in a xenogeneic animal model. *Haematologica* 2008; **93**: 1457-1465 [PMID: 18728032 DOI: 10.3324/haematol.12553]

49 **François S**, Bensidhoum M, Mouiseddine M, Mazurier C, Allenet B, Semont A, Frick J, Saché A, Bouchet S, Thierry D, Gourmelon P, Gorin NC, Chapel A. Local irradiation not only induces homing of human mesenchymal stem cells at exposed sites but promotes their widespread engraftment to multiple organs: a study of their quantitative distribution after irradiation damage. *Stem Cells* 2006; **24**: 1020-1029 [PMID: 16339642 DOI: 10.1634/stemcells.2005-0260]

50 **Sémont A**, François S, Mouiseddine M, François A, Saché A, Frick J, Thierry D, Chapel A. Mesenchymal stem cells increase self-renewal of small intestinal epithelium and accelerate structural recovery after radiation injury. *Adv Exp Med Biol* 2006; **585**: 19-30 [PMID: 17120774]

51 **Klopp AH**, Spaeth EL, Dembinski JL, Woodward WA, Munshi A, Meyn RE, Cox JD, Andreeff M, Marini FC. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. *Cancer Res* 2007; **67**: 11687-11695 [PMID: 18089798 DOI: 10.1158/0008-5472.CAN-07-1406]

52 **Benderitter M**, Gourmelon P, Bey E, Chapel A, Clairand I, Prat M, Lataillade JJ. New emerging concepts in the medical management of local radiation injury. *Health Phys* 2010; **98**: 851-857 [PMID: 20445393 DOI: 10.1097/HP.0b013e3181c9f79a]

53 **Sackstein R**. The bone marrow is akin to skin: HCELL and the biology of hematopoietic stem cell homing. *J Investig Dermatol Symp Proc* 2004; **9**: 215-223 [PMID: 15369216 DOI: 10.1111/j.0022-]

54 **Sackstein R**, Merzaban JS, Cain DW, Dagia NM, Spencer JA, Lin CP, Wohlgemuth R. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. *Nat Med* 2008; **14**: 181-187 [PMID: 18193058 DOI: 10.1038/nm1703]

55 **Moll NM**, Ransohoff RM. CXCL12 and CXCR4 in bone marrow physiology. *Expert Rev Hematol* 2010; **3**: 315-322 [PMID: 21082982 DOI: 10.1586/ehm.10.16]

56 **Nagasawa T**, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, Yoshida N, Kikutani H, Kishimoto T. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. *Nature* 1996; **382**: 635-638 [PMID: 8757135 DOI: 10.1038/382635a0]

57 **Zou YR**, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. *Nature* 1998; **393**: 595-599 [PMID: 9634238 DOI: 10.1038/31269]

58 **Wynn RF**, Hart CA, Corradi-Perini C, O'Neill L, Evans CA, Wraith JE, Fairbairn LJ, Bellantuono I. A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. *Blood* 2004; **104**: 2643-2645 [PMID: 15251986 DOI: 10.1182/blood-2004-02-0526]

59 **Von Lüttichau I**, Notohamiprodjo M, Wechselberger A, Peters C, Henger A, Seliger C, Djafarzadeh R, Huss R, Nelson PJ. Human adult CD34- progenitor cells functionally express the chemokine receptors CCR1, CCR4, CCR7, CXCR5, and CCR10 but not CXCR4. *Stem Cells Dev* 2005; **14**: 329-336 [PMID: 15969628 DOI: 10.1089/scd.2005.14.329]

60 **Gao H**, Priebe W, Glod J, Banerjee D. Activation of signal transducers and activators of transcription 3 and focal adhesion kinase by stromal cell-derived factor 1 is required for migration of human mesenchymal stem cells in response to tumor cell-conditioned medium. *Stem Cells* 2009; **27**: 857-865 [PMID: 19350687 DOI: 10.1002/stem.23]

61 **Wang Y**, Fu W, Zhang S, He X, Liu Z, Gao D, Xu T. CXCR-7 receptor promotes SDF-1α-induced migration of bone marrow mesenchymal stem cells in the transient cerebral ischemia/reperfusion rat hippocampus. *Brain Res* 2014; **1575**: 78-86 [PMID: 24924806 DOI: 10.1016/j.brainres.2014.05.035]

62 **Lourenco S**, Teixeira VH, Kalber T, Jose RJ, Floto RA, Janes SM. Macrophage migration inhibitory factor-CXCR4 is the dominant chemotactic axis in human mesenchymal stem cell recruitment to tumors. *J Immunol* 2015; **194**: 3463-3474 [PMID: 25712213 DOI: 10.4049/jimmunol.1402097]

63 **Son BR**, Marquez-Curtis LA, Kucia M, Wysoczynski M, Turner AR, Ratajczak J, Ratajczak MZ, Janowska-Wieczorek A. Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. *Stem Cells* 2006; **24**: 1254-1264 [PMID: 16410389 DOI: 10.1634/stemcells.2005-0271]

64 **Ryu CH**, Park SA, Kim SM, Lim JY, Jeong CH, Jun JA, Oh JH, Park SH, Oh WI, Jeun SS. Migration of human umbilical cord blood mesenchymal stem cells mediated by stromal cell-derived factor-1/CXCR4 axis via Akt, ERK, and p38 signal transduction pathways. *Biochem Biophys Res Commun* 2010; **398**: 105-110 [PMID: 20558135 DOI: 10.1016/j.bbrc.2010.06.043]

65 **Qiu Y**, Marquez-Curtis LA, Janowska-Wieczorek A. Mesenchymal stromal cells derived from umbilical cord blood migrate in response to complement C1q. *Cytotherapy* 2012; **14**: 285-295 [PMID: 22264191 DOI: 10.3109/14653249.2011.651532]

66 **Shi M**, Li J, Liao L, Chen B, Li B, Chen L, Jia H, Zhao RC. Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD/SCID mice. *Haematologica* 2007; **92**: 897-904 [PMID: 17606439 DOI: 10.3324/haematol.10669]

67 **Yu Q**, Liu L, Lin J, Wang Y, Xuan X, Guo Y, Hu S. SDF-1α/CXCR4 Axis Mediates The Migration of Mesenchymal Stem Cells to The Hypoxic-Ischemic Brain Lesion in A Rat Model. *Cell J* 2015; **16**: 440-447 [PMID: 25685734]

68 **Ponte AL**, Marais E, Gallay N, Langonné A, Delorme B, Hérault O, Charbord P, Domenech J. The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. *Stem Cells* 2007; **25**: 1737-1745 [PMID: 17395768 DOI: 10.1634/stemcells.2007-0054]

69 **Bhakta S**, Hong P, Koc O. The surface adhesion molecule CXCR4 stimulates mesenchymal stem cell migration to stromal cell-derived factor-1 in vitro but does not decrease apoptosis under serum deprivation. *Cardiovasc Revasc Med* 2006; **7**: 19-24 [PMID: 16513519 DOI: 10.1016/j.carrev.2005.10.008]

70 **Honczarenko M**, Le Y, Swierkowski M, Ghiran I, Glodek AM, Silberstein LE. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. *Stem Cells* 2006; **24**: 1030-1041 [PMID: 16253981 DOI: 10.1634/stemcells.2005-0319]

71 **Ip JE**, Wu Y, Huang J, Zhang L, Pratt RE, Dzau VJ. Mesenchymal stem cells use integrin beta1 not CXC chemokine receptor 4 for myocardial migration and engraftment. *Mol Biol Cell* 2007; **18**: 2873-2882 [PMID: 17507648 DOI: 10.1091/mbc.E07-02-0166]

72 **Segers VF**, Van Riet I, Andries LJ, Lemmens K, Demolder MJ, De Becker AJ, Kockx MM, De Keulenaer GW. Mesenchymal stem cell adhesion to cardiac microvascular endothelium: activators and mechanisms. *Am J Physiol Heart Circ Physiol* 2006; **290**: H1370-H1377 [PMID: 16243916 DOI: 10.1152/ajpheart.00523.2005]

73 **Rüster B**, Göttig S, Ludwig RJ, Bistrian R, Müller S, Seifried E, Gille J, Henschler R. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. *Blood* 2006; **108**: 3938-3944 [PMID: 16896152 DOI: 10.1182/blood-2006-05-025098]

74 **Steingen C**, Brenig F, Baumgartner L, Schmidt J, Schmidt A, Bloch W. Characterization of key mechanisms in transmigration and invasion of mesenchymal stem cells. *J Mol Cell Cardiol* 2008; **44**: 1072-1084 [PMID: 18462748 DOI: 10.1016/j.yjmcc.2008.03.010]

75 **Nagase H**, Woessner JF. Matrix metalloproteinases. *J Biol Chem* 1999; **274**: 21491-21494 [PMID: 10419448 DOI: 10.1074/jbc.274.31.21491]

76 **De Becker A**, Van Hummelen P, Bakkus M, Vande Broek I, De Wever J, De Waele M, Van Riet I. Migration of culture-expanded human mesenchymal stem cells through bone marrow endothelium is regulated by matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-3. *Haematologica* 2007; **92**: 440-449 [PMID: 17488654 DOI: 10.3324/haematol.10475]

77 **Ries C**, Egea V, Karow M, Kolb H, Jochum M, Neth P. MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines. *Blood* 2007; **109**: 4055-4063 [PMID: 17197427 DOI: 10.1182/blood-2006-10-051060]

78 **Smith H**, Whittall C, Weksler B, Middleton J. Chemokines stimulate bidirectional migration of human mesenchymal stem cells across bone marrow endothelial cells. *Stem Cells Dev* 2012; **21**: 476-486 [PMID: 21513440 DOI: 10.1089/scd.2011.0025]

79 **Balasubramanian S**, Venugopal P, Sundarraj S, Zakaria Z, Majumdar AS, Ta M. Comparison of chemokine and receptor gene expression between Wharton's jelly and bone marrow-derived mesenchymal stromal cells. *Cytotherapy* 2012; **14**: 26-33 [PMID: 22091833 DOI: 10.3109/14653249.2011.605119]

80 **Baek SJ**, Kang SK, Ra JC. In vitro migration capacity of human adipose tissue-derived mesenchymal stem cells reflects their expression of receptors for chemokines and growth factors. *Exp Mol Med* 2011; **43**: 596-603 [PMID: 21847008 DOI: 10.3858/emm.2011.43.10.069]

81 **Chamberlain G**, Wright K, Rot A, Ashton B, Middleton J. Murine mesenchymal stem cells exhibit a restricted repertoire of functional chemokine receptors: comparison with human. *PLoS One* 2008; **3**: e2934 [PMID: 18698345 DOI: 10.1371/journal.pone.0002934]

82 **Hemeda H**, Jakob M, Ludwig AK, Giebel B, Lang S, Brandau S. Interferon-gamma and tumor necrosis factor-alpha differentially affect cytokine expression and migration properties of mesenchymal stem cells. *Stem Cells Dev* 2010; **19**: 693-706 [PMID: 20067407 DOI: 10.1089/scd.2009.0365]

83 **Ringe J**, Strassburg S, Neumann K, Endres M, Notter M, Burmester GR, Kaps C, Sittinger M. Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2. *J Cell Biochem* 2007; **101**: 135-146 [PMID: 17295203 DOI: 10.1002/jcb.21172]

84 **Kim SM**, Kim DS, Jeong CH, Kim DH, Kim JH, Jeon HB, Kwon SJ, Jeun SS, Yang YS, Oh W, Chang JW. CXC chemokine receptor 1 enhances the ability of human umbilical cord blood-derived mesenchymal stem cells to migrate toward gliomas. *Biochem Biophys Res Commun* 2011; **407**: 741-746 [PMID: 21439934 DOI: 10.1016/j.bbrc.2011.03.093]

85 **Majumdar MK**, Keane-Moore M, Buyaner D, Hardy WB, Moorman MA, McIntosh KR, Mosca JD. Characterization and functionality of cell surface molecules on human mesenchymal stem cells. *J Biomed Sci* 2003; **10**: 228-241 [PMID: 12595759]

86 **Kern S**, Eichler H, Stoeve J, Klüter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. *Stem Cells* 2006; **24**: 1294-1301 [PMID: 16410387]

87 **Reinisch A**, Etchart N, Thomas D, Hofmann NA, Fruehwirth M, Sinha S, Chan CK, Senarath-Yapa K, Seo EY, Wearda T, Hartwig UF, Beham-Schmid C, Trajanoski S, Lin Q, Wagner W, Dullin C, Alves F, Andreeff M, Weissman IL, Longaker MT, Schallmoser K, Majeti R, Strunk D. Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation. *Blood* 2015; **125**: 249-260 [PMID: 25406351 DOI: 10.1182/blood-2014-04-572255]

88 **Al-Nbaheen M**, Vishnubalaji R, Ali D, Bouslimi A, Al-Jassir F, Megges M, Prigione A, Adjaye J, Kassem M, Aldahmash A. Human stromal (mesenchymal) stem cells from bone marrow, adipose tissue and skin exhibit differences in molecular phenotype and differentiation potential. *Stem Cell Rev* 2013; **9**: 32-43 [PMID: 22529014 DOI: 10.1007/s12015-012-9365-8]

89 **Peng L**, Jia Z, Yin X, Zhang X, Liu Y, Chen P, Ma K, Zhou C. Comparative analysis of mesenchymal stem cells from bone marrow, cartilage, and adipose tissue. *Stem Cells Dev* 2008; **17**: 761-773 [PMID: 18393634 DOI: 10.1089/scd.2007.0217]

90 **Tondreau T**, Meuleman N, Stamatopoulos B, De Bruyn C, Delforge A, Dejeneffe M, Martiat P, Bron D, Lagneaux L. In vitro study of matrix metalloproteinase/tissue inhibitor of metalloproteinase production by mesenchymal stromal cells in response to inflammatory cytokines: the role of their migration in injured tissues. *Cytotherapy* 2009; **11**: 559-569 [PMID: 19551542 DOI: 10.1080/14653240903051541]

91 **Forte G**, Minieri M, Cossa P, Antenucci D, Sala M, Gnocchi V, Fiaccavento R, Carotenuto F, De Vito P, Baldini PM, Prat M, Di Nardo P. Hepatocyte growth factor effects on mesenchymal stem cells: proliferation, migration, and differentiation. *Stem Cells* 2006; **24**: 23-33 [PMID: 16100005 DOI: 10.1634/stemcells.2004-0176]

92 **van de Kamp J**, Jahnen-Dechent W, Rath B, Knuechel R, Neuss S. Hepatocyte growth factor-loaded biomaterials for mesenchymal stem cell recruitment. *Stem Cells Int* 2013; **2013**: 892065 [PMID: 23861688 DOI: 10.1155/2013/892065]

93 **Phipps MC**, Xu Y, Bellis SL. Delivery of platelet-derived growth factor as a chemotactic factor for mesenchymal stem cells by bone-mimetic electrospun scaffolds. *PLoS One* 2012; **7**: e40831 [PMID: 22808271 DOI: 10.1371/journal.pone.0040831]

94 **Rombouts WJ**, Ploemacher RE. Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. *Leukemia* 2003; **17**: 160-170 [PMID: 12529674]

95 **Strioga M**, Viswanathan S, Darinskas A, Slaby O, Michalek J. Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. *Stem Cells Dev* 2012; **21**: 2724-2752 [PMID: 22468918 DOI: 10.1089/scd.2011.0722]

96 **Wiehe JM**, Kaya Z, Homann JM, Wöhrle J, Vogt K, Nguyen T, Rottbauer W, Torzewski J, Fekete N, Rojewski M, Schrezenmeier H, Moepps B, Zimmermann O. GMP-adapted overexpression of CXCR4 in human mesenchymal stem cells for cardiac repair. *Int J Cardiol* 2013; **167**: 2073-2081 [PMID: 22673499 DOI: 10.1016/j.ijcard.2012.05.065]

97 **Yukawa H**, Watanabe M, Kaji N, Okamoto Y, Tokeshi M, Miyamoto Y, Noguchi H, Baba Y, Hayashi S. Monitoring transplanted adipose tissue-derived stem cells combined with heparin in the liver by fluorescence imaging using quantum dots. *Biomaterials* 2012; **33**: 2177-2186 [PMID: 22192539 DOI: 10.1016/j.biomaterials.2011.12.009]

98 **Li Y**, Yu X, Lin S, Li X, Zhang S, Song YH. Insulin-like growth factor 1 enhances the migratory capacity of mesenchymal stem cells. *Biochem Biophys Res Commun* 2007; **356**: 780-784 [PMID: 17382293]

99 **Duijvestein M**, Wildenberg ME, Welling MM, Hennink S, Molendijk I, van Zuylen VL, Bosse T, Vos AC, de Jonge-Muller ES, Roelofs H, van der Weerd L, Verspaget HW, Fibbe WE, te Velde AA, van den Brink GR, Hommes DW. Pretreatment with interferon-γ enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis. *Stem Cells* 2011; **29**: 1549-1558 [PMID: 21898680 DOI: 10.1002/stem.698]

100 **Fan H**, Zhao G, Liu L, Liu F, Gong W, Liu X, Yang L, Wang J, Hou Y. Pre-treatment with IL-1β enhances the efficacy of MSC transplantation in DSS-induced colitis. *Cell Mol Immunol* 2012; **9**: 473-481 [PMID: 23085948 DOI: 10.1038/cmi.2012.40]

101 **Kim YS**, Noh MY, Kim JY, Yu HJ, Kim KS, Kim SH, Koh SH. Direct GSK-3β inhibition enhances mesenchymal stromal cell migration by increasing expression of β-PIX and CXCR4. *Mol Neurobiol* 2013; **47**: 811-820 [PMID: 23288365 DOI: 10.1007/s12035-012-8393-3]

102 **Yu Q**, Chen L, You Y, Zou C, Zhang Y, Liu Q, Cheng F. Erythropoietin combined with granulocyte colony‑stimulating factor enhances MMP-2 expression in mesenchymal stem cells and promotes cell migration. *Mol Med Rep* 2011; **4**: 31-36 [PMID: 21461559 DOI: 10.3892/mmr.2010.387]

103 **Marquez-Curtis LA**, Janowska-Wieczorek A. Enhancing the migration ability of mesenchymal stromal cells by targeting the SDF-1/CXCR4 axis. *Biomed Res Int* 2013; **2013**: 561098 [PMID: 24381939 DOI: 10.1155/2013/561098]

104 **Annabi B**, Lee YT, Turcotte S, Naud E, Desrosiers RR, Champagne M, Eliopoulos N, Galipeau J, Béliveau R. Hypoxia promotes murine bone-marrow-derived stromal cell migration and tube formation. *Stem Cells* 2003; **21**: 337-347 [PMID: 12743328]

105 **Vertelov G**, Kharazi L, Muralidhar MG, Sanati G, Tankovich T, Kharazi A. High targeted migration of human mesenchymal stem cells grown in hypoxia is associated with enhanced activation of RhoA. *Stem Cell Res Ther* 2013; **4**: 5 [PMID: 23295150 DOI: 10.1186/scrt153]

106 **Yu X**, Lu C, Liu H, Rao S, Cai J, Liu S, Kriegel AJ, Greene AS, Liang M, Ding X. Hypoxic preconditioning with cobalt of bone marrow mesenchymal stem cells improves cell migration and enhances therapy for treatment of ischemic acute kidney injury. *PLoS One* 2013; **8**: e62703 [PMID: 23671625 DOI: 10.1371/journal.pone.0062703]

107 **Hung SC**, Pochampally RR, Hsu SC, Sanchez C, Chen SC, Spees J, Prockop DJ. Short-term exposure of multipotent stromal cells to low oxygen increases their expression of CX3CR1 and CXCR4 and their engraftment in vivo. *PLoS One* 2007; **2**: e416 [PMID: 17476338]

108 **Liu H**, Xue W, Ge G, Luo X, Li Y, Xiang H, Ding X, Tian P, Tian X. Hypoxic preconditioning advances CXCR4 and CXCR7 expression by activating HIF-1α in MSCs. *Biochem Biophys Res Commun* 2010; **401**: 509-515 [PMID: 20869949 DOI: 10.1016/j.bbrc.2010.09.076]

109 **Valorani MG**, Montelatici E, Germani A, Biddle A, D'Alessandro D, Strollo R, Patrizi MP, Lazzari L, Nye E, Otto WR, Pozzilli P, Alison MR. Pre-culturing human adipose tissue mesenchymal stem cells under hypoxia increases their adipogenic and osteogenic differentiation potentials. *Cell Prolif* 2012; **45**: 225-238 [PMID: 22507457 DOI: 10.1111/j.1365-2184.2012.00817.x]

110 **Crowder SW**, Horton LW, Lee SH, McClain CM, Hawkins OE, Palmer AM, Bae H, Richmond A, Sung HJ. Passage-dependent cancerous transformation of human mesenchymal stem cells under carcinogenic hypoxia. *FASEB J* 2013; **27**: 2788-2798 [PMID: 23568779 DOI: 10.1096/fj.13-228288]

111 **Bensidhoum M**, Chapel A, Francois S, Demarquay C, Mazurier C, Fouillard L, Bouchet S, Bertho JM, Gourmelon P, Aigueperse J, Charbord P, Gorin NC, Thierry D, Lopez M. Homing of in vitro expanded Stro-1- or Stro-1+ human mesenchymal stem cells into the NOD/SCID mouse and their role in supporting human CD34 cell engraftment. *Blood* 2004; **103**: 3313-3319 [PMID: 14715641 DOI: 10.1182/blood-2003-04-1121]

112 **Bobis-Wozowicz S**, Miekus K, Wybieralska E, Jarocha D, Zawisz A, Madeja Z, Majka M. Genetically modified adipose tissue-derived mesenchymal stem cells overexpressing CXCR4 display increased motility, invasiveness, and homing to bone marrow of NOD/SCID mice. *Exp Hematol* 2011; **39**: 686-696.e4 [PMID: 21426925 DOI: 10.1016/j.exphem.2011.03.004]

113 **Kumar S**, Ponnazhagan S. Bone homing of mesenchymal stem cells by ectopic alpha 4 integrin expression. *FASEB J* 2007; **21**: 3917-3927 [PMID: 17622670 DOI: 10.1096/fj.07-8275com]

114 **Kim H**, Kim JS. A guide to genome engineering with programmable nucleases. *Nat Rev Genet* 2014; **15**: 321-334 [PMID: 24690881 DOI: 10.1038/nrg3686]

115 **Bessis N**, GarciaCozar FJ, Boissier MC. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. *Gene Ther* 2004; **11** Suppl 1: S10-S17 [PMID: 15454952 DOI: 10.1038/sj.gt.3302364]

116 **Otani K**, Yamahara K, Ohnishi S, Obata H, Kitamura S, Nagaya N. Nonviral delivery of siRNA into mesenchymal stem cells by a combination of ultrasound and microbubbles. *J Control Release* 2009; **133**: 146-153 [PMID: 18976686 DOI: 10.1016/j.jconrel.2008.09.088]

117 **Teo GS**, Ankrum JA, Martinelli R, Boetto SE, Simms K, Sciuto TE, Dvorak AM, Karp JM, Carman CV. Mesenchymal stem cells transmigrate between and directly through tumor necrosis factor-α-activated endothelial cells via both leukocyte-like and novel mechanisms. *Stem Cells* 2012; **30**: 2472-2486 [PMID: 22887987 DOI: 10.1002/stem.1198]

118 **Sarkar D**, Vemula PK, Zhao W, Gupta A, Karnik R, Karp JM. Engineered mesenchymal stem cells with self-assembled vesicles for systemic cell targeting. *Biomaterials* 2010; **31**: 5266-5274 [PMID: 20381141 DOI: 10.1016/j.biomaterials.2010.03.006]

119 **Won YW**, Patel AN, Bull DA. Cell surface engineering to enhance mesenchymal stem cell migration toward an SDF-1 gradient. *Biomaterials* 2014; **35**: 5627-5635 [PMID: 24731711 DOI: 10.1016/j.biomterials.2014.03.070]

120 **Cheng H**, Byrska-Bishop M, Zhang CT, Kastrup CJ, Hwang NS, Tai AK, Lee WW, Xu X, Nahrendorf M, Langer R, Anderson DG. Stem cell membrane engineering for cell rolling using peptide conjugation and tuning of cell-selectin interaction kinetics. *Biomaterials* 2012; **33**: 5004-5012 [PMID: 22494889 DOI: 10.1016/j.biomaterials.2012.03.065]

121 **Lo CY**, Antonopoulos A, Dell A, Haslam SM, Lee T, Neelamegham S. The use of surface immobilization of P-selectin glycoprotein ligand-1 on mesenchymal stem cells to facilitate selectin mediated cell tethering and rolling. *Biomaterials* 2013; **34**: 8213-8222 [PMID: 23891082 DOI: 10.1016/j.biomaterials.2013.07.033]

122 **Sipkins DA**, Wei X, Wu JW, Runnels JM, Côté D, Means TK, Luster AD, Scadden DT, Lin CP. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. *Nature* 2005; **435**: 969-973 [PMID: 15959517 DOI: 10.1038/nature03703]

123 **Chen A**, Zheng G, Tykocinski ML. Hierarchical costimulator thresholds for distinct immune responses: application of a novel two-step Fc fusion protein transfer method. *J Immunol* 2000; **164**: 705-711 [PMID: 10623813 DOI: 10.4049/jimmunol.164.2.705]

124 **Ko IK**, Kean TJ, Dennis JE. Targeting mesenchymal stem cells to activated endothelial cells. *Biomaterials* 2009; **30**: 3702-3710 [PMID: 19375791 DOI: 10.1016/j.biomaterials.2009.03.038]

125 **Ko IK**, Kim BG, Awadallah A, Mikulan J, Lin P, Letterio JJ, Dennis JE. Targeting improves MSC treatment of inflammatory bowel disease. *Mol Ther* 2010; **18**: 1365-1372 [PMID: 20389289 DOI: 10.1038/mt.2010.54]

126 **Ponomaryov T**, Peled A, Petit I, Taichman RS, Habler L, Sandbank J, Arenzana-Seisdedos F, Magerus A, Caruz A, Fujii N, Nagler A, Lahav M, Szyper-Kravitz M, Zipori D, Lapidot T. Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. *J Clin Invest* 2000; **106**: 1331-1339 [PMID: 11104786 DOI: 10.1172/JCI10329]

127 **Zhao Z**, Watt C, Karystinou A, Roelofs AJ, McCaig CD, Gibson IR, De Bari C. Directed migration of human bone marrow mesenchymal stem cells in a physiological direct current electric field. *Eur Cell Mater* 2011; **22**: 344-358 [PMID: 22125259]

128 **Li L**, Wu S, Liu Z, Zhuo Z, Tan K, Xia H, Zhuo L, Deng X, Gao Y, Xu Y. Ultrasound-Targeted Microbubble Destruction Improves the Migration and Homing of Mesenchymal Stem Cells after Myocardial Infarction by Upregulating SDF-1/CXCR4: A Pilot Study. *Stem Cells Int* 2015; **2015**: 691310 [PMID: 26074977 DOI: 10.1155/2015/691310]

129 **Landázuri N**, Tong S, Suo J, Joseph G, Weiss D, Sutcliffe DJ, Giddens DP, Bao G, Taylor WR. Magnetic targeting of human mesenchymal stem cells with internalized superparamagnetic iron oxide nanoparticles. *Small* 2013; **9**: 4017-4026 [PMID: 23766267 DOI: 10.1002/smll.201300570]

130 **Acosta SA**, Tajiri N, Hoover J, Kaneko Y, Borlongan CV. Intravenous Bone Marrow Stem Cell Grafts Preferentially Migrate to Spleen and Abrogate Chronic Inflammation in Stroke. *Stroke* 2015; **46**: 2616-2627 [PMID: 26219646 DOI: 10.1161/STROKEAHA.115.009854]

131 **Fernández-García M**, Yañez RM, Sánchez-Domínguez R, Hernando-Rodriguez M, Peces-Barba M, Herrera G, O'Connor JE, Segovia JC, Bueren JA, Lamana ML. Mesenchymal stromal cells enhance the engraftment of hematopoietic stem cells in an autologous mouse transplantation model. *Stem Cell Res Ther* 2015; **6**: 165 [PMID: 26345192 DOI: 10.1186/s13287-015-0155-5]

132 **Liu X**, Duan B, Cheng Z, Jia X, Mao L, Fu H, Che Y, Ou L, Liu L, Kong D. SDF-1/CXCR4 axis modulates bone marrow mesenchymal stem cell apoptosis, migration and cytokine secretion. *Protein Cell* 2011; **2**: 845-854 [PMID: 22058039 DOI: 10.1007/s13238-011-1097-z]

133 **Kavanagh DP**, Suresh S, Newsome PN, Frampton J, Kalia N. Pretreatment of Mesenchymal Stem Cells Manipulates Their Vasculoprotective Potential While Not Altering Their Homing Within the Injured Gut. *Stem Cells* 2015; **33**: 2785-2797 [PMID: 26124062 DOI: 10.1002/stem.2061]

134 **Szabó E**, Fajka-Boja R, Kriston-Pál É, Hornung Á, Makra I, Kudlik G, Uher F, Katona RL, Monostori É, Czibula Á. Licensing by Inflammatory Cytokines Abolishes Heterogeneity of Immunosuppressive Function of Mesenchymal Stem Cell Population. *Stem Cells Dev* 2015; **24**: 2171-2180 [PMID: 26153898 DOI: 10.1089/scd.2014.0581]

135 **Naaldijk Y**, Johnson AA, Ishak S, Meisel HJ, Hohaus C, Stolzing A. Migrational changes of mesenchymal stem cells in response to cytokines, growth factors, hypoxia, and aging. *Exp Cell Res* 2015; **338**: 97-104 [PMID: 26335540 DOI: 10.1016/j.yexcr.2015.08.019]

136 **Choudhery MS**, Khan M, Mahmood R, Mehmood A, Khan SN, Riazuddin S. Bone marrow derived mesenchymal stem cells from aged mice have reduced wound healing, angiogenesis, proliferation and anti-apoptosis capabilities. *Cell Biol Int* 2012; **36**: 747-753 [PMID: 22352320 DOI: 10.1042/CBI20110183]


137 **Wang H**, Zhao T, Xu F, Li Y, Wu M, Zhu D, Cong X, Liu Y. How important is differentiation in the therapeutic effect of mesenchymal stromal cells in liver disease? *Cytotherapy* 2014; **16**: 309-318 [PMID: 24239106 DOI: 10.1016/j.jcyt.2013.07.011]

138 **Ullah M**, Eucker J, Sittinger M, Ringe J. Mesenchymal stem cells and their chondrogenic differentiated and dedifferentiated progeny express chemokine receptor CCR9 and chemotactically migrate toward CCL25 or serum. *Stem Cell Res Ther* 2013; **4**: 99 [PMID: 23958031 DOI: 10.1186/scrt310]


139 **Cholewa D**, Stiehl T, Schellenberg A, Bokermann G, Joussen S, Koch C, Walenda T, Pallua N, Marciniak-Czochra A, Suschek CV, Wagner W. Expansion of adipose mesenchymal stromal cells is affected by human platelet lysate and plating density. *Cell Transplant* 2011; **20**: 1409-1422 [PMID: 21396157 DOI: 10.3727/096368910X557218]

140 **Chamberlain G**, Smith H, Rainger GE, Middleton J. Mesenchymal stem cells exhibit firm adhesion, crawling, spreading and transmigration across aortic endothelial cells: effects of chemokines and shear. *PLoS One* 2011; **6**: e25663 [PMID: 21980522 DOI: 10.1371/journal.pone.0025663]

# P-Reviewer: Chapel A, Lui PPY, Mustapha N, Phinney DG S-Editor: Ji FF L-Editor: E-Editor:



**Figure 1 Overview of the homing molecules that are expressed on human mesenchymal stromal cells and known to be involved in the different steps of the bone marrow homing of mesenchymal stromal cells.** EC: Endothelial cell; BM: Basement membrane; CD: Cluster of differentiation; SDF-1: Stromal cell derived factor 1; VLA-4: Very late antigen 4; VCAM-1: Vascular cell adhesion molecule 1; TIMP: Tissue inhibitor of metalloproteinases; MMP: Matrix metalloproteinase; MT1-MMP: Membrane type 1 matrix metalloproteinase); MSC: Mesenchymal stromal cell.



**Figure 2 Schematic overview of the different strategies that can be used to improve homing in the different steps of mesenchymal stromal cell migration.** CD: Cluster of differentiation; EC: Endothelial cell; BM: Basement membrane; HCELL: Hematopoietic cell E-/L-selectin ligand; PSGL-1: P-selectin glycoprotein ligand-1; SLEX: Sialyl Lewis X; SDF-1: Stromal cell derived factor 1; VLA-4: Very late antigen 4; VCAM-1: Vascular cell adhesion molecule 1; Ab: Antibody; TIMP: Tissue inhibitor of metalloproteinases; MMP: Matrix metalloproteinase; EPO: Erythropoietin; G-CSF: Granulocyte colony stimulating factor; MSC: Mesenchymal stromal cell.

**Table 1 Overview of the homing molecules expressed on human mesenchymal stromal cells**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Group** | **Molecule** | **Source** | **Transcript** | **Protein** | **Functional assay** |
| **Chemokine receptors** | CCR1[70,77-82] | BM[70,77-79,81]  WJ[79]  AT[80]  PB[82] | Yes[70,77,79,80] | Yes[70,77- 82] | *In vitro* migration[70,77,78,80], *in vivo* tail vein injection in mice for tissue distribution[77] |
| CCR2[68,78,81,82] | BM[68,78,81,82] | Yes[68,82] | Yes[68,78,81,82] | *In vitro* migration[68,78,82] |
| CCR3[68,78,81,82,83] | BM[68,78,81,83]  PB[82] | Yes [68] | Yes[68,78,81,82,82] | *In vitro* migration[68,78] |
| CCR4[68,77,78,82] | BM[68,77,78,82] | Yes[68,77, 82] | Yes[68,77, 78]  No[82] | *In vitro* migration[68,77,78,82], *in vivo* tail vein injection in mice for tissue distribution[77] |
| CCR5[68,78,81-83] | BM[68,78,81,83]  PB[82] | Yes[68] | Yes[68,78,81,82] | *In vitro* migration[68,78] |
| CCR6[78,81,83] | BM[78,81,83] | Yes[82] | Yes[78,82] | *In vitro* migration[78] |
| CCR7[70,78,80- 83] | BM[70,78,81,83]  AT[80]  PB[82] | Yes[70,80,83] | Yes[70,78,80- 83] | *In vitro* migration[70,78,83] |
| CCR8[78,82,83] | BM[78,83]  PB[82] | Yes[82] | Yes[78,82,83] | *In vitro* migration[78] |
| CCR9[70,78,81-83] | BM[70,78,81,83]  PB[82] | Yes[70,83] | Yes[70,78,81- 83] | *In vitro* migration[70,78] |
| CCR10[77,78,81,83] | BM[77,78,81,83] | Yes[77,83] | Yes[77,78,81] | *In vitro* migration[77,78], *in vivo* tail vein injection in mice for tissue distribution[77] |
| CXCR1[78,81,82,84] | CB[84]  BM[78,81,82]  PB[82] | Yes[83,84] | Yes[78,81,82,84] | *In vitro* migration[78,83,84], *in vivo* injection in brain[84] |
| CXCR2[62,78,81- 83] | BM[62,78,81,83]  PB[82] | Yes [62, 83] | Yes[62,78,81- 83] | *In vitro* migration[62,78,83], *in vivo* lung metastasis model[62] |
| CXCR3[78,81-83] | BM[78,81,83]  PB[82] | Yes[83] | Yes[78,81-83] | *In vitro* migration[78] |
| CXCR4[60,62,65,66,68,70,76,78,80-83,85,90] | BM[60,62,68,70,76,78,81,83,85]  CB[65,85,90]  Foetal BM[66]  AT[80]  PB[82] | Yes[60,62,66,68,70,76,80,83,85] | Yes[62,65,66,68,70,76,78,80-83,85,90] | *In vitro* migration[60,62,76,65,66,68,70,78,80,83,85,90], *in vivo* lung metastasis model[62], tail vein injection in sublethally irradiated mice[66] |
| CXCR5[68,70,77- 83] | BM[68,70,77,78,81,83]  WJ[79]  AT[80]  PB[82] | Yes[68,70,77,79,80,83] | Yes[68,70,77-83] | *In vitro* migration[68,70,77,78,80], *in vivo* tail vein injection in mice for tissue distribution[77] |
| CXCR6[70,78,80-83] | BM[70,78,81,83]  AT[80]  PB[82] | Yes[70,80,83] | Yes[70,78,80- 83] | *In vitro* migration[70,78,80] |
| CXCR7[60,82] | BM[60]  PB[82] | Yes[60] | Yes[82] | *In vitro* migration[60] |
| CX3CR[82] | BM[82]  PB[82] | Yes[82] | Yes[82] |  |
| XCR[82,82] | BM[82]  PB[82] | Yes[82] | Yes[82] |  |
| **Adhesion molecules** | VCAM-1[74,85,86] | BM[74,85,86]  CB[86]  AT[86] | Yes[85] | Yes[85,86] | *In vitro* migration[74] |
| ICAM-2[85] | BM[85] | Yes[85] | Yes[85] |  |
| CD62[11,17,54,86-89] | BM[11,54,86-89]  CB[17,86,87,89]  AT[86-89]  Skin[87] |  | Yes[11,17,54,86-89] | *In vivo* homing in a mouse model[54] |
| LFA-3[85] | BM[85] | Yes[85] | Yes[85] |  |
| Integrin α1[11,85,87] | BM[11,85,87]  CB[87]  AT[87]  Skin[87] | Yes[85] | Yes[11,85,87] |  |
| Integrin α2[85] | BM[85] | Yes[85] | Yes[85] |  |
| Integrin α3[11,85] | BM[11,85] | Yes[85] | Yes[11,85] |  |
| Integrin α5[11,85] | BM[11,85] | Yes[85] | Yes[11,85] |  |
| Integrin α6[85] | BM[85] | Yes[85] | Yes[85] |  |
| Integrin αv[85] | BM[85] | Yes[85] | Yes[85] |  |
| Integrin β1[11,86-88] | BM[11,86-88]  CB [86,87]  AT[86-88]  Skin[87] |  | Yes[11,86-88] |  |
| Integrin β3[85] | BM[85] | Yes[85] | Yes[85] |  |
| Integrin β4[85] | BM[85] | Yes[85] | Yes[85] |  |
| ALCAM[17,87] | BM[87]  AT[87]  CB[17,87] |  | Yes[17] |  |
| **Proteases** | MMP-1[90] | BM [90] | Yes[90] | Yes[90] | *In vitro* migration[90] |
| MMP-2[65,68,74,76,77,85,90] | BM[68,76,77,85,90]  CB[85] | Yes[68,76,77,85,90] | Yes[65,68,76,77,85,90] | *In vitro* migration[65,68,74,76,77,85,90] |
| MMP-13[68,90] | BM[68,90] | Yes[68,90] | Yes[68,90] | *In vitro* migration[68,90] |
| MT1-MMP[68,77,85] | BM[68,77,85]  CB[85] | Yes[68,77, 85] | Yes[68,77, 85] | *In vitro* migration[68,77, 85] |
| TIMP-1 [68, 77, 90] | BM[68,77,90] | Yes[68,77,90] | Yes[68,77,90] | *In vitro* migration[68,77,90] |
| TIMP-2 [68, 90] | BM[68,77,90] | Yes[68,77,90] | Yes[68,77,90] | *In vitro* migration[68,77,90] |
| TIMP-3 [76] | BM[76] | Yes[76] | Yes[76] | *In vitro* migration[76] |
| **Growth factor receptors** | c-met (HGF-R)[68,80,85] | BM[68,85]  CB[85]  AT[80] | Yes[68,80, 85] | Yes[68,85]  No[80] | *In vitro* migration[85,68] |
| PDGFRα[68,80,87] | BM[68,87]  AT[80,87]  CB[87]  Skin[87] | Yes[68,80] | Yes[68,80,87] | *In vitro* migration[68,80] |
| PDGFRβ[68,80,87] | BM[68,87]  AT[80,87]  CB[87]  Skin[87] | Yes[68,80] | Yes[68,80,87] | *In vitro* migration[68,80] |
| FGF-R1[80] | AT[80] | Yes[80] | Yes[80] | *In vitro* migration[80] |
| FGF-R2[68] | BM[68] | Yes[68] | Yes[68] | *In vitro* migration[68] |
| EGF-R[68,78] | BM[68,78]  AT[80] | Yes[68,80] | Yes[68,80] | *In vitro* migration[68,80] |
| IGF-R1[68] | BM[68] | Yes[68] | Yes[68] | *In vitro* migration[68] |
| TIE-2[68] | BM[68] | Yes[68] | Yes[68] | *In vitro* migration[68] |
| TGFRB2[80] | AT[80] | Yes[80] | Yes[80] | *In vitro* migration[80] |
| TNFRSF1A[80] | AT[80] | Yes[80] | Yes[80] | *In vitro* migration[80] |

BM: Bone marrow; CB: Cord blood; AT: Adipose tissue; WJ: Wharton’s Jelly; VCAM: Vascular cell adhesion molecule; ICAM: Intercellular adhesion molecule; CD: Cluster of differentiation; LFA: Lymphocyte function associated antigen; ALCAM: Activated leukocyte cell adhesion molecule; MMP: Matrix metalloproteinase; TIMP: Tissue inhibitor of metalloproteinase; HGF: Hepatocyte growth factor; PDGFR: Platelet-derived growth factor receptor; FGF-R: Fibroblast growth factor receptor; EGF-R: Epidermal growth factor receptor; IGF-R: Insulin-like growth factor receptor; TIE: Tyrosine kinase with immunoglobulin-like and EGF-like domains; TGFR: Transforming growth factor receptor; TNFRSF: Tumour necrosis factor receptor superfamily.